var data={"title":"Treatment protocols for multiple myeloma","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Treatment protocols for multiple myeloma</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-multiple-myeloma/contributors\" class=\"contributor contributor_credentials\">Tim Brenner, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-multiple-myeloma/contributors\" class=\"contributor contributor_credentials\">Shrina Duggal, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-multiple-myeloma/contributors\" class=\"contributor contributor_credentials\">Jim Natale, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-multiple-myeloma/contributors\" class=\"contributor contributor_credentials\">Scott M Wirth, PharmD, BCOP</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-multiple-myeloma/contributors\" class=\"contributor contributor_credentials\">John W Mucenski, PharmD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-multiple-myeloma/contributors\" class=\"contributor contributor_credentials\">Rebecca F Connor, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-multiple-myeloma/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 21, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H4993546\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following material represents a subset of chemotherapy regimens that are used for the treatment of patients with multiple myeloma. <strong>This is</strong> <strong>not an exhaustive list</strong>; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with multiple myeloma. Additional regimens may be added over time, particularly as treatment for multiple myeloma evolves.</p><p>This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with multiple myeloma. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=overview-of-the-management-of-multiple-myeloma\" class=\"medical medical_review\">&quot;Overview of the management of multiple myeloma&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=management-of-multiple-myeloma-in-resource-poor-settings\" class=\"medical medical_review\">&quot;Management of multiple myeloma in resource-poor settings&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=selection-of-initial-chemotherapy-for-symptomatic-multiple-myeloma\" class=\"medical medical_review\">&quot;Selection of initial chemotherapy for symptomatic multiple myeloma&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-multiple-myeloma\" class=\"medical medical_review\">&quot;Treatment of relapsed or refractory multiple myeloma&quot;</a>.)</p><p/><p>These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</p><p class=\"headingAnchor\" id=\"H4993660\"><span class=\"h1\">REGIMENS</span></p><p class=\"headingAnchor\" id=\"H936049102\"><span class=\"h2\">Bortezomib (Velcade) plus cyclophosphamide and dexamethasone (VCD or CyBorD)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F50061\" class=\"graphic graphic_table graphicRef50061 \">table 1</a>)</p><p class=\"headingAnchor\" id=\"H936049127\"><span class=\"h2\">Bortezomib (Velcade) plus melphalan and prednisone (VMP)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F55107\" class=\"graphic graphic_table graphicRef55107 \">table 2</a>)</p><p class=\"headingAnchor\" id=\"H936049152\"><span class=\"h2\">Lenalidomide (Revlimid) plus dexamethasone (Rd)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F56451\" class=\"graphic graphic_table graphicRef56451 \">table 3</a>)</p><p class=\"headingAnchor\" id=\"H936049177\"><span class=\"h2\">Melphalan plus prednisone and thalidomide (MPT)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F53179\" class=\"graphic graphic_table graphicRef53179 \">table 4</a>)</p><p class=\"headingAnchor\" id=\"H936049202\"><span class=\"h2\">Thalidomide plus dexamethasone (Td)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F82300\" class=\"graphic graphic_table graphicRef82300 \">table 5</a>)</p><p class=\"headingAnchor\" id=\"H2081898\"><span class=\"h2\">Bortezomib (Velcade) plus lenalidomide (Revlimid) and dexamethasone (VRd)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F91054\" class=\"graphic graphic_table graphicRef91054 \">table 6</a>)</p><p><a href=\"topic.htm?path=bortezomib-drug-information\" class=\"drug drug_general\">Bortezomib</a><strong> (Velcade), </strong><a href=\"topic.htm?path=thalidomide-drug-information\" class=\"drug drug_general\">thalidomide</a><strong> (Thalomid), and </strong><a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a><strong> (VTd)</strong> &mdash; (<a href=\"image.htm?imageKey=ONC%2F101205\" class=\"graphic graphic_table graphicRef101205 \">table 7</a>)</p><p class=\"headingAnchor\" id=\"H2778895042\"><span class=\"h2\">Ixazomib, lenalidomide, and dexamethasone (IRd)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=HEME%2F106536\" class=\"graphic graphic_table graphicRef106536 \">table 8</a>)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"topicVersionRevision\">Topic 85687 Version 12.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li><a href=\"#H4993546\" id=\"outline-link-H4993546\">INTRODUCTION</a></li><li><a href=\"#H4993660\" id=\"outline-link-H4993660\">REGIMENS</a><ul><li><a href=\"#H936049102\" id=\"outline-link-H936049102\">Bortezomib (Velcade) plus cyclophosphamide and dexamethasone (VCD or CyBorD)</a></li><li><a href=\"#H936049127\" id=\"outline-link-H936049127\">Bortezomib (Velcade) plus melphalan and prednisone (VMP)</a></li><li><a href=\"#H936049152\" id=\"outline-link-H936049152\">Lenalidomide (Revlimid) plus dexamethasone (Rd)</a></li><li><a href=\"#H936049177\" id=\"outline-link-H936049177\">Melphalan plus prednisone and thalidomide (MPT)</a></li><li><a href=\"#H936049202\" id=\"outline-link-H936049202\">Thalidomide plus dexamethasone (Td)</a></li><li><a href=\"#H2081898\" id=\"outline-link-H2081898\">Bortezomib (Velcade) plus lenalidomide (Revlimid) and dexamethasone (VRd)</a></li><li><a href=\"#H2778895042\" id=\"outline-link-H2778895042\">Ixazomib, lenalidomide, and dexamethasone (IRd)</a></li></ul></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/85687|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/50061\" class=\"graphic graphic_table\">- VCd CyBorD for multiple myeloma</a></li><li><a href=\"image.htm?imageKey=ONC/55107\" class=\"graphic graphic_table\">- VMP for multiple myeloma</a></li><li><a href=\"image.htm?imageKey=ONC/56451\" class=\"graphic graphic_table\">- Rd for multiple myeloma</a></li><li><a href=\"image.htm?imageKey=ONC/53179\" class=\"graphic graphic_table\">- MPT for multiple myeloma</a></li><li><a href=\"image.htm?imageKey=ONC/82300\" class=\"graphic graphic_table\">- Td for multiple myeloma</a></li><li><a href=\"image.htm?imageKey=ONC/91054\" class=\"graphic graphic_table\">- VRd for multiple myeloma</a></li><li><a href=\"image.htm?imageKey=ONC/101205\" class=\"graphic graphic_table\">- VTd for multiple myeloma</a></li><li><a href=\"image.htm?imageKey=HEME/106536\" class=\"graphic graphic_table\">- IRd for MM</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-multiple-myeloma-in-resource-poor-settings\" class=\"medical medical_review\">Management of multiple myeloma in resource-poor settings</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-management-of-multiple-myeloma\" class=\"medical medical_review\">Overview of the management of multiple myeloma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=selection-of-initial-chemotherapy-for-symptomatic-multiple-myeloma\" class=\"medical medical_review\">Selection of initial chemotherapy for symptomatic multiple myeloma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-multiple-myeloma\" class=\"medical medical_review\">Treatment of relapsed or refractory multiple myeloma</a></li></ul></div></div>","javascript":null}